Moderna TherapeuticsCambridge, Massachusetts, United States
Disclosure information not submitted.
220 - Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study
Monday, October 20, 20253:39 PM - 3:51 PM US ET
642 - mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial
Wednesday, October 22, 20251:57 PM - 2:09 PM US ET
